Thirty-three adults ages > 65 y with MCI were randomized to receive a supplement rich in the long-chain -3 PUFAs eicosapentaenoic acid ( EPA ; 1.67 g EPA + 0.16 g docosahexaenoic acid DHA/d ; n = 12 ) or DHA ( 1.55 g DHA + 0.40 g EPA/d ; n = 12 ) , versus -6 PUFA linoleic acid ( LA ; 2.2 g/d ; n = 9 ) for 6 mo. .